SCHEMBL6914624

SCHEMBL6914624

CC(=O)OCC1CCOC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.39
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
IRAK4 Q9NWZ3 2/20 0.36
NLRP3 Q96P20 2/20 0.36
PDK1 Q15118 1/20 0.36
GRM5 P41594 3/20 0.34
ALDH1A1 P00352 2/20 0.34
NSD2 O96028 1/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14677007 0.89 HDAC3 (0.39) AOC3HDAC3HDAC1HDAC2NLRP3
SCHEMBL13034065 0.88 NLRP3 (0.38) HDAC3HDAC1HDAC2IRAK4NLRP3
SCHEMBL3431890 0.84 AOC3 (0.41) AOC3HDAC3HDAC1HDAC2IRAK4
SCHEMBL15132111 0.84
SCHEMBL3431892 0.82 HDAC3 (0.38) AOC3HDAC3HDAC1HDAC2IRAK4
SCHEMBL3238105 0.82 ALDH1A1 (0.57) AOC3HDAC3HDAC1HDAC2IRAK4
SCHEMBL24409030 0.81 AOC3 (0.38) AOC3HDAC3HDAC1HDAC2IRAK4
SCHEMBL10257415 0.81 AOC3 (0.43) AOC3HDAC3HDAC1HDAC2IRAK4
SCHEMBL399191 0.81 HDAC3 (0.37) AOC3HDAC3HDAC1HDAC2GRM5
SCHEMBL12352115 0.81 HDAC3 (0.39) AOC3HDAC3HDAC1HDAC2IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6147233-A Process for the preparation of 3-methyltetrahydrofuran EASTMAN CHEMICAL COMPANY (US) 2000-11-14 US claimed
EP-3786165-A1 SYNTHETIC INTERMEDIATES FOR PRODUCING MACROCYCLES AS FACTOR XIA INHIBITORS Bristol-Myers Squibb Company (US) 2021-03-03 EP disclosed
EP-2534154-B1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-08-05 EP disclosed
WO-2019065283-A1 PYRIDAZINONE COMPOUND OR SALT THEREOF AND HERBICIDE CONTAINING SAME 石原産業株式会社 2019-04-04 WO disclosed
US-9802939-B2 Macrocycles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-10-31 US disclosed
US-20150112058-A1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-04-23 US disclosed
EP-1917269-B1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMA (US) 2011-10-26 EP disclosed
WO-2011100401-A1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-08-18 WO disclosed
US-20100210603-A1 NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE TUNG ROGER D 2010-08-19 US disclosed
US-20100210603-A1 NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE TUNG ROGER D 2010-08-19 US disclosed
US-7608632-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-27 US disclosed
US-7608632-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-27 US disclosed
US-20080293727-A1 Novel sulfonamide inhibitors of aspartyl protease TUNG ROGER D 2008-11-27 US disclosed
US-20080293727-A1 Novel sulfonamide inhibitors of aspartyl protease TUNG ROGER D 2008-11-27 US disclosed
US-7321063-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-01-22 US disclosed
US-7321063-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-01-22 US disclosed
WO-2004007418-A1 A PROCESS FOR THE PREPARATION OF 2-ACETOXYMETHYL-4 HALO-BUT-1-YL ACETATES RECORDATI S.A. (CH) 2004-01-22 WO disclosed
US-6147233-A Process for the preparation of 3-methyltetrahydrofuran EASTMAN CHEMICAL COMPANY (US) 2000-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150112058-A1 MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F11 AOC3 1729/4885HDAC3 990/4885HDAC1 815/4885
US-20100210603-A1 NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE SPINT2, PRSS1, DNPEP AOC3 4562/4885HDAC3 990/4885HDAC1 775/4885
US-20080293727-A1 Novel sulfonamide inhibitors of aspartyl protease SPINT2, PRSS1, DNPEP AOC3 4562/4885HDAC3 990/4885HDAC1 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.